The FDA has approved Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide), from Gilead Sciences, as a complete regimen for the...
Gilead Sciences announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines...
Gilead Sciences has announced 96-week results from two Phase III studies (Study 104 and study 111) evaluating its once-daily single...
Gilead Sciences, Inc. announced that the European Commission has granted marketing authorization for the once-daily single tablet regimen Genvoya (elvitegravir...
Gilead Sciences has submitted a New Drug Application to the FDA for an investigational, once-daily single tablet regimen containing elvitegravir...
This study is to confirm the dose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) single tablet regimen (STR) in HIV-1 infected, antiretroviral (ARV)...
Gilead Sciences announced detailed 48-week data from an open-label Phase III study (Study 109) evaluating its investigational once-daily single tablet...
Gilead Sciences, Inc. announced 144-week data from two Phase III studies (Studies 104 and 111) evaluating the safety and efficacy...
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of...
Gilead Sciences, Inc. announced that two Phase III clinical trials (Studies 104 and 111) evaluating an investigational once-daily single tablet...